Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2018
- Pages: 302
- Published: April 2018
- Report Code: GMDHC10372IDB
Global Markets Direct’s, ‘Idiopathic Pulmonary Fibrosis – Pipeline Review, H1 2018’, provides an overview of the Idiopathic Pulmonary Fibrosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis
– The report reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Idiopathic Pulmonary Fibrosis therapeutics and enlists all their major and minor projects
– The report assesses Idiopathic Pulmonary Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Idiopathic Pulmonary Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Abeome Corp
AdAlta Ltd
Aeolus Pharmaceuticals Inc
Allinky Biopharma
AnaMar AB
apceth Biopharma GmbH
Asahi Kasei Corp
BerGenBio ASA
Biogen Inc
Bioneer Corp
Boehringer Ingelheim GmbH
BreStem Therapeutics Inc
Bristol-Myers Squibb Co
Celgene Corp
Chiesi Farmaceutici SpA
Compugen Ltd
Cynata Therapeutics Ltd
F. Hoffmann-La Roche Ltd
FibroGen Inc
FibroStatin SL
Galapagos NV
Galecto Biotech AB
GenKyoTex SA
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Global Blood Therapeutics Inc
iBio Inc
Inventiva
Isarna Therapeutics GmbH
Kadmon Corp LLC
Kasiak Research Pvt Ltd
Kyorin Pharmaceutical Co Ltd
Lung Therapeutics Inc
Medicenna Therapeutics Corp
Merck & Co Inc
Miragen Therapeutics Inc
Mission Therapeutics Ltd
Moerae Matrix Inc
Novartis AG
Nuevolution AB
Nuformix Plc
OliX Pharmaceuticals Inc
Pharmaxis Ltd
Promedior Inc
ProMetic Life Sciences Inc
Pulmatrix Inc
Re-Pharm Ltd
Redx Pharma Plc
Respira Therapeutics Inc
Reviva Pharmaceuticals Inc
Ribomic Inc
Saje Pharma LLC
Samumed LLC
Shionogi & Co Ltd
Sorrento Therapeutics Inc
Taiho Pharmaceutical Co Ltd
Telocyte LLC
Therabron Therapeutics Inc
Unity Biotechnology Inc
Vicore Pharma AB
X-Rx Inc
Yuhan Corp
Zai Lab Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.